On June 2, ASCO Annual Meeting 2017, the main event of the year for specialists in the field of oncology, had started.
Annually in Chicago, USA, more than 30,000 medical and pharmaceutical workers gather to discuss modern methods of treatment and innovative drugs.
This year, the congress will present the results of a multicenter, open-label Phase II safety and efficacy study of Quizinostat in combination with Paclitaxel + Carboplatin chemotherapy in patients with metastatic or locally advanced epithelial ovarian cancer, primary peritoneal carcinoma or fallopian tube carcinoma resistant to the first line Chemotherapy with platinum and paclitaxel, which was carried out by the contract-research organization IPHARMA.
On June 3, the report will be presented in the framework of the session of posters Fedyanin Mikhail Mikhailovich, Ph.D., doctor-oncologist of the Department of Clinical Pharmacology and Chemotherapy of the Russian Cancer Research Center. N.N. Blokhin, the leading medical center of this study.
Quizinostat (histone deacetylase inhibitor, HDAC) - a new generation drug was developed by the Russian pharmaceutical company NewVac (the ChemRar Group of Companies) together with Janssen Pharmaceutica (Johnson & Johnson LLC).
The HDAC of the new generation inhibitor has a longer lasting effect, the ability to use in the form of tablets, activity against hematological malignancies and solid tumors.
Poster "A multicenter phase II study of the efficacy and safety of Quisinostat"